Google’s Olympics Misstep and the Real AI Opportunity

While Google showcases AI’s ability to mimic human sentimentality, it misses the forest for the trees. The real innovation, the true potential of AI, lies not in replacing human expression but in enhancing human lives, particularly those of our rapidly aging population. The post Google’s Olympics Misstep and the Real AI Opportunity appeared first on…

Read More

From FOMO to FOMU: A Framework for Getting AI Right

Healthcare is a highly regulated industry, and any use of AI within it is dealing with the most sensitive data. In order to ensure you’re not putting you, your company or patients at risk, consider an evaluation framework for any AI tool that considers these three things. The post From FOMO to FOMU: A Framework…

Read More

Watching Where and How You’re Walking

By MIKE MAGEE In a speech to the American Philosophical Society in January, 1946, J. Robert Oppenheimer said, “We have made a thing …that has altered abruptly and profoundly the nature of the world…We have raised again the question of whether science is good for man, of whether it is good to learn about the…

Read More

What is the right sample size for a qualitative interview study?

The answer to this question, of course, depends on your specific research question. However, it is helpful to review what has been done in previous literature. A paper by Vasileiou et al. (2018) conducted a systematic literature review of all published studies using a single-interview-per-participant designs within three health-related journals: British Medical Journal (BMJ), British…

Read More

Change to UK Rare Disease Approval Process

The Times reports that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) is revising it’s approach to how it approves new medicines that treat rare diseases. How? Principally by allowing for single arm trials with real-world ‘digital twin’ controls as well as expediting the approval process. The new plan, which is being launched on…

Read More